Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Antivirals Stories

2013-03-28 08:27:52

- CMX001 data will also be presented in a poster session RESEARCH TRIANGLE PARK, N.C., March 28, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced presentations related to the use of its broad spectrum antiviral compound CMX001 at the European Group for Blood and Marrow Transplantation's (EBMT) Annual Meeting being held April 7-10, 2013 in London, United Kingdom. EBMT is a...

2013-03-20 23:02:51

polyDNA recommends that the public consider Gene-Eden-VIR, a natural herpes remedy with no side effects. Rochester, NY (PRWEB) March 20, 2013 polyDNA has learned that a new paper spotlights the status of recent antiviral research. (1) In one section of the paper, the authors highlight the state of affairs on anti-herpes medications. As of March 2013, a helicase-primase inhibitor (HPI) under the generic name of AIC316 and developed by AiCuris has now proceeded to phase I/II clinical trials....

2013-03-20 08:26:18

EMERYVILLE, Calif., March 20, 2013 /PRNewswire/-- Adamas Pharmaceuticals, Inc. will present research results today from its Nurelin(TM )(amantadine HCl extended release capsules) program demonstrating the benefit of amantadine in traumatic brain injury (TBI) at the 65(th) American Academy of Neurology (AAN) Annual Meeting being held in San Diego, CA. Nurelin, a once-daily extended release formulation of amantadine intended for nighttime administration, is being evaluated in a Phase 2/3...

2013-03-14 08:28:24

RESEARCH TRIANGLE PARK, N.C., March 14, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced today that Michael D. Rogers, Ph.D., has joined the company as Chief Development Officer. Dr. Rogers will be responsible for overseeing chemistry, manufacturing, toxicology and project management as well as the advancement of compounds from the Chimerix Chemical Library. "We are extremely pleased to have...

2013-02-20 08:27:50

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced the appointment of Ernest Mario, Ph.D., as Chairman of its Board of Directors. "Ernie brings to Chimerix a unique breadth and depth of experiences across large and early stage pharmaceutical firms. His knowledge will be invaluable as we seek to progress our lead compound, CMX001, through Phase 3...

2013-02-19 08:31:46

RESEARCH TRIANGLE PARK, N.C., Feb. 19, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today released data from presentations at the BMT Tandem Meetings supporting the broad spectrum antiviral activity and emerging safety profile of CMX001. CMX001 is an oral nucleotide lipid-conjugate anticipated to start a Phase 3 study later this year. "These findings demonstrate CMX001's potential to be a safe and...

HIV And Other Deadly Viruses Blocked By Natural Protein
2013-02-12 04:56:31

Jason Pierce, MSN, MBA, RN for redOrbit.com — Your Universe Online A study by a team of UCLA-led researchers, published in the journal Immunity in January 2013, may aid in the development of broad spectrum medications aimed at combating existing and newly emerging viral threats. Broad spectrum antivirals can be used to treat diseases caused by a variety of different viruses. The development of these medications is a domestic biodefense goal of the National Institute of Allergy and...

2013-02-04 08:25:18

RESEARCH TRIANGLE PARK, N.C., Feb. 4, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing antivirals in areas of high unmet medical need, today announced that three abstracts related to the broad-spectrum antiviral compound CMX001 will be presented at the BMT Tandem Meetings being held February 13-17 in Salt Lake City. The BMT Tandem Meetings are the combined annual meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the...

2013-01-31 15:18:11

People with hepatitis C and chronic liver disease who relapsed or failed to respond to initial treatment are unlikely to improve on interferon retreatment. In fact, they may face an increased risk of dying sooner, and are likely to experience a variety of adverse effects, according to an updated systematic review published in The Cochrane Library. Hepatitis C affects around 170 million people worldwide. In some cases, infection leads to chronic liver disease, liver failure or liver cancer,...

2013-01-17 20:22:34

SAN DIEGO and PHILADELPHIA, Jan. 17, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that purchasers of Hemispherx Biopharma, Inc. (NYSE: HEB) ("Hemispherx" or the "Company") have filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania. The complaint alleges the Company and certain of its officers and directors violated the Securities Exchange Act of 1934 between March 19, 2012 and December 17, 2012 (the "Class Period")....